Pulsetto
Edited by Samael A. Tejada, Founder & Editor-in-Chief
Tip: press play, then lock your phone or switch apps — the article keeps reading.
UAB Pulsetto · Vilnius, Lithuania · bilateral neck-worn tcVNS wellness device · no FDA clearance
Product + cost
Pulsetto delivers electrical stimulation through conductive gel on the neck. Reported 2026 prices are about $269 for Lite and $296 for FIT; FIT X launched in September 2026. Gel is a consumable. The optional Premium app is about $139/year, and HRV tracking—the metric emphasized in marketing—is paywalled.
Device-specific evidence
The flagship company-funded pilot recruited 40 people, with 37 completers over four weeks and no sham arm. Hair cortisol fell (p=0.013); questionnaires improved in both unilateral and bilateral groups, leaving placebo and expectancy uncontrolled. The company’s claim of a peer-reviewed RCT in Neuroscience Applied could not be independently verified: no DOI or PMID was found. A single-session crossover EEG study remains unpublished; migraine (n=20) and ankylosing-spondylitis pilots were observational.
Mitochondrial claim
There is no Pulsetto evidence on ATP, respiration, mtDNA, biogenesis or any other mitochondrial endpoint. General tcVNS trials show plausible physiological engagement: Gurel’s sham-controlled study reduced sympathetic stress responses, and a 2026 cervical-tcVNS study lowered systolic blood pressure. A 2024 review links VNS to mitochondrial pathways, but nearly all of that literature is preclinical and device-independent. Pulsetto’s own white paper calls vagal fiber recruitment “a biologically plausible inference rather than a directly verified endpoint.” See the vagus-nerve evidence guide.
Regulatory status + comparator
Pulsetto is not FDA-cleared or approved in the US. FCC certification concerns consumer-electronics emissions; it is not medical review. The company positions it as a general-wellness product “not intended to diagnose, treat, cure, or prevent any disease.” CE marking cited by the company does not establish medical efficacy. By contrast, prescription gammaCore is FDA-cleared for specific headache indications, uses a clinical protocol and carries labeled cautions.
Safety
Skin irritation is the most common noninvasive-VNS adverse effect; tingling, muscle twitching and rare tinnitus flares are reported. Long-term Pulsetto safety data are absent. Company contraindications include pacemakers, pregnancy, epilepsy, heart conditions and metal implants in the head or neck. Because bilateral unsupervised neck stimulation differs from gammaCore precedent and lies near the carotid sinus, people with carotid plaque, arrhythmias or blood-pressure disorders should consult a physician.
Verdict
Plausible modality, unproven device, zero mitochondrial data. No published sham-controlled Pulsetto RCT and no HRV outcome data were located. The FIT X has no published study. The device may feel relaxing; that is not evidence of mitochondrial repair or disease treatment.
All device-specific science is company-funded with no independent replication. Pulsetto pays affiliates, offers $30 referral credits and uses NBA ambassadors Domantas Sabonis, Jonas Valančiūnas and Matas Buzelis. A €20 million valuation, €2 million ScaleWolf investment and company-announced $40M+ revenue create strong marketing incentives. “100,000+ users” and “86% satisfaction” are internal surveys, not clinical evidence.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.